Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ABP 
ABPRO CORP (ABP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ABP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2
1 Year Target Price $2
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.55% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.83M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 1 | Beta -0.04 | 52 Weeks Range 0.16 - 13.00 | Updated Date 06/30/2025 |
52 Weeks Range 0.16 - 13.00 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.43 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -5464.48% |
Management Effectiveness
Return on Assets (TTM) -212.91% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14813114 | Price to Sales(TTM) 70.09 |
Enterprise Value 14813114 | Price to Sales(TTM) 70.09 | ||
Enterprise Value to Revenue 80.95 | Enterprise Value to EBITDA - | Shares Outstanding 60787300 | Shares Floating 30186959 |
Shares Outstanding 60787300 | Shares Floating 30186959 | ||
Percent Insiders 48.34 | Percent Institutions 2.6 |
Analyst Ratings
Rating 1 | Target Price 2 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
ABPRO CORP
Company Overview
History and Background
ABPRO CORP is a biopharmaceutical company focused on the discovery and development of therapeutic antibody-based products. Founded in 2013, it has grown through private funding and strategic partnerships, reaching clinical trial stages with several candidates.
Core Business Areas
- Oncology: Developing antibody therapeutics for various cancer types, including solid tumors and hematological malignancies.
- Autoimmune Diseases: Creating antibody-based treatments for autoimmune disorders.
Leadership and Structure
The company is led by its CEO, Dr. Patricio Gariglio, and a management team with expertise in antibody engineering and clinical development. The organizational structure is typical of a biotech, with distinct research, development, and clinical operations divisions.
Top Products and Market Share
Key Offerings
- Bimagrumab: A fully human monoclonal antibody targeting activin type II receptors for muscle wasting disorders and oncology applications. Currently in clinical trials, no current market share, but potential competitors include companies developing similar therapies for muscle wasting, such as Novartis and Eli Lilly.
- AB201: An anti-PD-L1 antibody for cancer immunotherapy. Currently in clinical trials. Competitors include Roche (Tecentriq), Merck (Keytruda), and Bristol-Myers Squibb (Opdivo).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and regulatory scrutiny. Growth is driven by innovation in biologics and personalized medicine.
Positioning
ABPRO CORP is a small to mid-sized player in the competitive antibody therapeutics market. Its competitive advantages lie in its proprietary antibody engineering platform and targeted approach to specific disease areas. The company is focused on developing innovative therapies for unmet medical needs.
Total Addressable Market (TAM)
The total addressable market for antibody therapeutics is estimated to be in the hundreds of billions of dollars, covering multiple indications. ABPRO CORP is positioning itself to capture a portion of this TAM through its innovative pipeline and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary antibody engineering platform
- Experienced management team
- Diverse pipeline of antibody therapeutics
- Strategic partnerships with leading institutions
Weaknesses
- Limited financial resources compared to larger competitors
- Reliance on successful clinical trial outcomes
- Limited commercialization experience
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into new disease areas
- Successful clinical trial readouts
- Potential for breakthrough therapies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- Roche (ROG.SW)
- Merck (MRK)
- Bristol-Myers Squibb (BMY)
Competitive Landscape
ABPRO CORP faces intense competition from established pharmaceutical giants. Its success hinges on its innovative technology and targeted approach. The company is at an early stage but it is competing with established companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is driven by private funding rounds and strategic partnerships.
Future Projections: Future growth depends on successful clinical trial outcomes and potential licensing agreements.
Recent Initiatives: Recent initiatives include advancing Bimagrumab and AB201 into later-stage clinical trials and expanding its research collaborations.
Summary
ABPRO CORP is a promising biopharmaceutical company focused on antibody therapeutics, with a proprietary platform and pipeline in oncology and autoimmune diseases. As a private company with limited financial disclosure, it faces risks related to funding, clinical trials, and competition. Successful clinical outcomes and strategic partnerships are key for its future growth, but it has good support of investors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Press releases
- Analyst reports
- Clinical trial registries
Disclaimers:
The information provided is based on publicly available sources and should not be considered investment advice. The financial information is limited due to the company being private. Market share data may vary depending on the specific product and geographic region.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ABPRO CORP
Exchange NYSE | Headquaters Woburn, MA, United States | ||
IPO Launch date - | CEO & Chairman of the Board Mr. Jin Wook Suk | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://abpro.co |
Full time employees 6 | Website https://abpro.co | ||
Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in different combinations and orientations to create fit for purpose novel full-length multi-specific antibody constructs. The company's lead product candidates include ABP-102, a next generation immuno-oncology TetraBi antibody targeting HER2 and CD3 is developed for the treatment of HER2+ solid tumors, including breast and gastric cancers; and ABP-201, a TetraBi antibody format that simultaneously inhibit VEGF and ANG-2 for the treatment of vascular diseases of the eye, including diabetic macular edema and wet age-related macular degeneration. It also develops ABP-110, a TetraBi antibody targeting GPC3 and CD3 for the treatment of hepatocellular carcinoma; and ABP-150, a TetraBi antibody targeting claudin 18.2 and CD3 for the treatment of gastric cancers. The company has strategic partnership with Celltrion Inc. and Abpro Bio International, Inc. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.